(Total Views: 606)
Posted On: 04/07/2020 11:19:24 PM
Post# of 145254
![](/m/assets/46931549/no_avatar_available_thumb.jpg)
Re: thriftycents #26220
That would be a special case — the same as if the patient had cancer (or one of our many other potential indications). Leronlimab would almost certainty address the HIV with its well-established MOA as an entry inhibitor, and it would likely address the immune deficiency with its other MOA, though the evidence for that is still being gathered.
![](/m/images/thumb-up.png)
![](/m/images/thumb-down.png)